Alprazolam is among the most frequently prescribed benzodiazepines in the United States and is the drug most people mean when they say "Xanax." Its defining characteristic is a short half-life — typically 6 to 12 hours — which gives it a faster, more noticeable onset than longer-acting benzodiazepines but also means it clears the system relatively quickly.
This pharmacokinetic profile has direct clinical consequences. The faster onset makes alprazolam feel more immediately effective for acute anxiety, which is one reason it is commonly used and commonly misused — the rapid relief is perceptible. The rapid clearance, however, is what produces interdose rebound: as levels fall between doses, some patients experience a return of anxiety that can feel worse than before they took the medication. This rebound cycle can reinforce reliance on the drug.
Alprazolam's FDA approvals cover anxiety disorders and panic disorder. It is not approved for seizure management. Extended-release tablets (Xanax XR) were developed to smooth out the peak-and-trough fluctuations of the immediate-release form, though the underlying half-life of the drug itself doesn't change.
Because alprazolam clears quickly, abrupt discontinuation can trigger withdrawal within hours. Symptoms can be severe and in some cases medically serious. Never stop without a prescriber-supervised taper plan — the rapid clearance makes this more urgent than with longer-acting benzodiazepines.